PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-50.43%
Both yoy net incomes decline, with TRVN at -8.08%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
7.46%
D&A growth well above TRVN's 6.10%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
46.91%
Some yoy growth while TRVN is negative at -4.81%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
9.40%
Less SBC growth vs. TRVN's 25.58%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-262.74%
Negative yoy working capital usage while TRVN is 69.09%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-225.01%
Negative yoy AP while TRVN is 100.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
155.76%
Growth well above TRVN's 41.87%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
9.40%
Some yoy increase while TRVN is negative at -3.82%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-30.81%
Negative yoy CFO while TRVN is 9.97%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
49.68%
CapEx growth well above TRVN's 74.68%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Purchases well above TRVN's 62.96%. Michael Burry would see major cash outflow into securities vs. competitor’s approach, risking near-term FCF.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Less 'other investing' outflow yoy vs. TRVN's 728.91%. David Dodd would see a stronger short-term cash position unless competitor invests more wisely.
82.07%
Lower net investing outflow yoy vs. TRVN's 696.27%, preserving short-term cash. David Dodd would confirm expansions remain sufficient.
-1.11%
We cut debt repayment yoy while TRVN is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
207.88%
We slightly raise equity while TRVN is negative at -100.03%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.